| Abstrakt: |
INTRODUCTION Three years have elapsed since the first trial in susceptible children of an attenuated measles virus propagated in tissue cultures of chick embryo cells.1 During this period of time it has been possible to enlarge our experience with the administration of vaccine to both normal children and those suffering from various disorders, to accumulate further data documenting the clinical and serological responses induced by this material, and to observe the prophylactic efficacy of vaccination in varying environmental situations. The initial study, undertaken in 1958, included only 13 residents of a state institution for the mentally deficient. More than 10,000 children have now received similar vaccine in one fashion or another. In addition to healthy children and a few adults, those vaccinated include individuals with tuberculosis, asthma, cystic fibrosis, rheumatoid arthritis, cerebral palsy, epilepsy, malnutrition, nephrosis, cardiac disease, adrenocortical hyperplasia, nephrogenic diabetes insipidus, phenylketonuria, sickle-cell trait, and leukemia. The age of vaccine |
